On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Cybin Corp. Leads Out in Growing Billion-Dollar Nutraceutical, Psychedelic Markets

  • Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion
  • Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments
  • As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market

Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces.

In 2019, the global nutraceutical market was valued at $382.51 billion. The market is also expected to grow at a compound annual growth rate (“CAGR”) of 8.3% over the next seven years. Consumers continue to embrace functional foods, or foods that offer benefits beyond basic nutrition, for their wellness benefits (http://ibn.fm/1UQMB).

At the same time, the psychedelic drugs market is also projected to reach $6.85 billion by 2027. That forecast is based on increased incidences of mental health disorders as well as growing acceptance of psychedelic drugs. The expected proliferation of psychedelics comes from continued research interest from major academic institutions (http://ibn.fm/g75oV).

Cybin is committed to advancing research and development (R&D) through its intellectual property portfolio in the psychedelic, pharmaceutical and nutraceutical spaces. Based on the company’s unique psilocybin extraction methods, delivery mechanisms and new formulations, a variety of indications for mental health will be addressed.

The company’s business model is structured around two wholly owned divisions across the pharmaceutical and nutraceutical sector: Serenity Life Sciences and Nature’s Journey Inc. Serenity Life Sciences is focused on advancing R&D of psilocybin-based pharmaceutical products. Psilocybin, a naturally occurring, non-habit-forming psychedelic compound derived from mushrooms, is experiencing a strong research revival.

Studies show promising results in the treatment of a number of mental health conditions such as anxiety, depression, PTSD, addiction, eating disorders, ADHD and other conditions (http://ibn.fm/2vOww). Cybin views mushroom-derived psychedelic medicines as brain boosters potentially capable of breaking negative thought patterns. Studies indicate that retraining thought processes with low doses of psychedelics help with mental health conditions affecting hundreds of millions of people worldwide.

Cybin’s Nature’s Journey Inc. is focused on nonpsychedelic medical mushroom extracts. Consumer trend forecasts indicate that adaptogenic mushrooms are the next wave of super nutraceuticals. These products are designed to optimize overall health by enhancing mental wellness, immune-boosting detoxification and general well-being.

Cybin offers a robust, diversified business model with compelling growth opportunities in dual, complimentary sectors. Therefore, investors looking for high-potential investments in growing markets should take note of the company’s two-pronged approach to the psychedelic pharmaceutical and nutraceutical mushroom markets.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

From Our Blog

Mushrooms’ Potential in Functional Foods Market Being Realized by Therapeutics Innovator Rritual Mushrooms

October 21, 2020

Emerging Wellness Foods Brand Rritual Mushrooms Inc. is developing plant-based superfood products to lead out a fledgling market segment that has a high degree of promise as consumer interest in functional foods increases While the mushroom therapeutics subcategory of products is still new and developing, analysts researching the overall functional foods market expect the industry […]

Rotate your device 90° to view site.